A5012619170- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Cancer Research and Treatments
- Biomedical Ethics and Regulation
- Pancreatic and Hepatic Oncology Research
- Intraperitoneal and Appendiceal Malignancies
- Colorectal and Anal Carcinomas
- Cervical Cancer and HPV Research
- Ovarian cancer diagnosis and treatment
- Nonmelanoma Skin Cancer Studies
- Occupational and environmental lung diseases
- Pituitary Gland Disorders and Treatments
- Adrenal and Paraganglionic Tumors
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Health Systems, Economic Evaluations, Quality of Life
- Gastrointestinal Tumor Research and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Metastasis and carcinoma case studies
- Virus-based gene therapy research
- Statistical Methods in Clinical Trials
The University of Texas MD Anderson Cancer Center
2016-2025
Emory University
2024-2025
University Hospitals of Leicester NHS Trust
2023-2024
Georgetown University
2022
The University of Texas Health Science Center at Houston
2021
Memorial Sloan Kettering Cancer Center
2020
Lexicon Pharmaceuticals (United States)
2019
Whipps Cross University Hospital
2016
Brigham and Women's Hospital
2012
Engineering Systems (United States)
2011
The incidence and prevalence of neuroendocrine tumors (NETs) are thought to be rising, but updated epidemiologic data lacking.To explore the evolving epidemiology investigate effect therapeutic advances on survival patients with NETs.A retrospective, population-based study using nationally representative from Surveillance, Epidemiology, End Results (SEER) program was conducted evaluate 64 971 NETs 1973 2012. Associated population were used determine annual age-adjusted incidence,...
Sepsis, a potentially fatal clinical syndrome, is mediated by an early (e.g., tumor necrosis factor and IL-1) late [e.g., high mobility group B-1 (HMGB1)] proinflammatory cytokine response to infection. Specifically targeting mediators has not been effective clinically, in part because peak mediator activity often passed before therapy can be initiated. Late-acting downstream effectors, such as HMGB1, that mediate sepsis lethality may more relevant therapeutic targets. Ethyl pyruvate (EP)...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine and Adrenal Gland Tumors focus on the diagnosis, treatment, management of patients with neuroendocrine tumors (NETs), adrenal tumors, pheochromocytomas, paragangliomas, multiple endocrine neoplasia. NETs are generally subclassified by site origin, stage, histologic characteristics. Appropriate diagnosis treatment often involves collaboration between specialists disciplines, using specific biochemical,...
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, paragangliomas. Management NETs relies heavily on site primary NET. These Insights summarize options 2018 updates to guidelines locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, thymus NETs.
Abstract This article is the result of North American Neuroendocrine Tumor Society consensus conference on medical management pancreatic neuroendocrine tumors from July 19 to 20, 2018. The guidelines panel consisted oncologists, pathologists, gastroenterologists, endocrinologists, and radiologists. reviewed a series questions regarding patients with as well surveillance after resection. available literature was for each question members voted controversial topics, recommendations were...
LBA588 Background: Currently, there is no universally accepted first line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and an unmet medical need remains in these patients (pts). Radioligand (RLT) innovative cancer treatment that crosses the traditional domains of systemic, radiation or surgical therapies. The Phase 3 NETTER-2 study (NCT03972488) evaluated [ 177 Lu]Lu-DOTA-TATE (hereafter Lu-DOTATATE) as 1L pts with Grade (G) 2 G3...
Abstract Background Metastatic high-grade neuroendocrine neoplasms (G3NENs) have limited treatment options after progression on platinum-based therapy. We addressed the role of Pembrolizumab in patients with previously treated metastatic G3NENs. Methods Two open-label, phase 2 studies enrolled G3NEN (Ki-67 > 20%) to receive at 200 mg I.V. every 3 weeks. Radiographic evaluation was conducted 9 weeks overall response rate as primary endpoint. Results Between November 2016 and May 2018, 29...
Spartalizumab, a humanized anti-programmed death protein 1 (PD-1) monoclonal antibody, was evaluated in patients with well-differentiated metastatic grade 1/2 neuroendocrine tumors (NET) and poorly-differentiated gastroenteropancreatic carcinomas (GEP-NEC). In this phase II, multicenter, single-arm study, received spartalizumab 400 mg every 4 weeks until confirmed disease progression or unacceptable toxicity. The primary endpoint overall response rate (ORR) according to blinded independent...
Malignant peritoneal mesothelioma (MPeM) is a rare but aggressive malignancy with limited treatment options. VEGF inhibition enhances efficacy of immune-checkpoint inhibitors by reworking the immunosuppressive tumor milieu. Efficacy and safety combined PD-L1 (atezolizumab) (bevacizumab) blockade (AtezoBev) was assessed in 20 patients advanced unresectable MPeM progression or intolerance to prior platinum-pemetrexed chemotherapy. The primary endpoint confirmed objective response rate per...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors immunoarchitectural patterns (IAPs) for all stages pediatric adult patients with NLPHL.
The aim of this study was to examine tumor-infiltrating lymphocytes (TILs) and their prognostic value in patients with pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy.Intratumoral CD4, CD8, FOXP3 were examined by immunohistochemistry using a computer-assisted quantitative analysis 136 PDAC who received therapy pancreaticoduodenectomy. results correlated clinicopathological parameters survival.High CD4 TILs treated associated high CD8 (P = 0.003), differentiation 0.04),...
We observed that some patients with well-differentiated neuroendocrine tumors (NET) who received peptide receptor radionuclide therapy (PRRT) Lutetium-177 ( 177 Lu) DOTATATE developed rapid disease progression biopsy-proven histologic transformation to carcinoma (NEC), an outcome has not been previously described. Therefore, we conducted a retrospective review of all G1-G2 NET at least one cycle PRRT our center from January 2019 December 2020. Among 152 patients, identified 7 whose...
Abstract Purpose: Appendiceal adenocarcinoma (AA) remains an orphan disease with limited treatment options for patients unable to undergo surgical resection. Evidence supporting the efficacy of combined VEGF and PD-1 inhibition in other tumor types provided a compelling rationale investigating this combination AA, where immune checkpoint inhibitors have not been explored previously. Experimental Design: We conducted prospective, single-arm phase II study evaluating safety atezolizumab...
// Amir Mehrvarz Sarshekeh 1 , Shailesh Advani Daniel M. Halperin Claudius Conrad 2 Chan Shen 3 James C. Yao and Arvind Dasari Department of Gastrointestinal Medical Oncology, The University Texas MD Anderson Cancer Center, Houston, TX 77030, USA Surgical Health Services Research, Correspondence to: Dasari, email: adasari@mdanderson.org Keywords: appendix, neuroendocrine, right hemicolectomy, survival, tumor size Received: May 09, 2017 Accepted: June 30,...
Neuroendocrine tumors (NETs) arise from enterochromaffin cells found in neuroendocrine tissues, with most occurring the gastrointestinal tract. The global incidence of NETs has increased past 15 years, likely due to better diagnostic methods. Small-bowel are frequently associated carcinoid syndrome (CS). Carcinoid diarrhea occurs 80% CS patients and poses a substantial symptomatic economic burden. Patients suffer flushing report corresponding impairment quality life, requiring changes daily...
619 Background: Neuroendocrine tumors (NETs) are relatively rare and heterogeneous arising throughout the aerodigestive tract, which incurable life-limiting when metastatic. Prior studies of checkpoint inhibitors in NET patients have yielded minimal evidence efficacy. Historically, effective therapies for advanced, progressive yield response rates less than 10% progression-free survival (PFS) durations approximately 11 months, as compared to 4.5 months with placebo. Methods: We undertook a...
Therapies for patients with advanced well-differentiated neuroendocrine tumors (NETs) have expanded but remain inadequate, dying of disease despite recent advances in NET therapy. While other cancers seen long-term control and tumor regression the application immunotherapies, initial prospective studies single-agent programmed cell death 1 inhibitors been disappointing.To evaluate response rate following treatment combination vascular endothelial growth factor inhibitor bevacizumab ligand...
4132 Background: RYZ101 ( 225 Ac-DOTATATE) is a first-in-class, highly potent alpha-emitting radiopharmaceutical in development for treating SSTR2+ solid tumors. Alpha-particles (as emitted by Ac) have shorter path length (40–100 μm) and higher linear energy transfer (80–100 keV/μm) than beta-particles, causing more frequent double-strand DNA breaks potentially cancer cell kill rates less damage to healthy tissues. ACTION-1 (NCT05477576) 2-part, global, randomized, controlled, open-label,...
Malignant pheochromocytomas (PHEOs)/paragangliomas (PGLs) are rare tumors for which clinical outcomes remain poorly defined and therapeutic options limited. Approximately 27% carry pathogenic germline succinate dehydrogenase (SDHx) mutations; the presence of such mutations has been correlated with response to temozolomide (TMZ). We aimed investigate association between in SDHx TMZ. retrospectively identified patients metastatic malignant PHEO/PGLs treated TMZ- based chemotherapy at...
TPS514 Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which represent approximately 70% of NETs, frequently develop metastatic disease with limited treatment options. Current standard therapies for well-differentiated high grade 2 and 3 GEP-NETs include cytoreductive procedures, somatostatin analogues, molecular targeted (everolimus or sunitinib), chemotherapy peptide receptor radionuclide therapy (PRRT), no specified sequence use. PRRT may stabilize induce objective...